Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Koffiekamer Terug naar discussie overzicht

Intellia Therapeutics 2024

167 Posts
Pagina: «« 1 ... 4 5 6 7 8 9 | Laatste | Omlaag ↓
  2. Hoger Lager 17 april 2024 16:56

    • Hoger Lager

      Lid sinds: 04 okt 2023

      Laatste bezoek: 31 mei 2024

    • Aanbevelingen

      Ontvangen: 225

      Gegeven: 264

    •    Aantal posts: 344

    quote:

    Rick96 schreef op 16 april 2024 15:48:

    Nog geen beste keuze geweest..
    Door de oorlog zijn de meeste koersen gedaald. Ik zit LT
  3. Hoger Lager 29 april 2024 17:08

    • Hoger Lager

      Lid sinds: 04 okt 2023

      Laatste bezoek: 31 mei 2024

    • Aanbevelingen

      Ontvangen: 225

      Gegeven: 264

    •    Aantal posts: 344

    Intellia Therapeutics, Inc.
    April 29, 2024 7:30 AM EDT
    Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
    Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up
    Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET
    CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts (25 mg, 50 mg and 75 mg).

    Presentation Details

    Title: CRISPR-based gene editing of KLKB1 resulted in long-term plasma kallikrein protein reduction and decreased attack rate in patients with hereditary angioedema: Updated results from a phase 1 study

    Session: Breakthroughs in management of Hereditary Angioedema

    Date and Time: Sunday, June 2, 2024, from 8:30 – 10:00 a.m. CET

    Presenter: Hilary Longhurst, M.D., Ph.D., FRCP, FRCPath, Senior Medical Officer at Auckland District Health Board and Honorary Associate Professor at University of Auckland, New Zealand, the trial’s principal investigator in New Zealand
167 Posts
Pagina: «« 1 ... 4 5 6 7 8 9 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.854
AB InBev 2 5.311
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 47.397
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 9.057
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 167
ADMA Biologics 1 32
Adomos 1 126
AdUX 2 457
Adyen 13 16.790
Aedifica 2 847
Aegon 3.257 320.450
AFC Ajax 537 7.029
Affimed NV 2 5.819
ageas 5.843 109.790
Agfa-Gevaert 13 1.904
Ahold 3.536 74.037
Air France - KLM 1.024 34.407
AIRBUS 1 2
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.779
Alfen 13 17.553
Allfunds Group 3 1.241
Almunda Professionals (vh Novisource) 651 4.248
Alpha Pro Tech 1 17
Alphabet Inc. 1 343
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.779
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.822 240.597
AMG 965 126.809
AMS 3 73
Amsterdam Commodities 303 6.527
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 384
Antonov 22.632 153.605
Aperam 91 14.220
Apollo Alternative Assets 1 17
Apple 5 322
Arcadis 251 8.630
Arcelor Mittal 2.024 318.815
Archos 1 1
Arcona Property Fund 1 272
arGEN-X 15 9.208
Aroundtown SA 1 190
Arrowhead Research 5 9.328
Ascencio 1 21
ASIT biotech 2 697
ASMI 4.107 37.795
ASML 1.762 77.991
ASR Nederland 18 4.181
ATAI Life Sciences 1 7
Atenor Group 1 347
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.826
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.701

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 02 juni

    1. Vergadering OPEC+

  2. 03 juni

    1. Inkoopmanagersindex industrie mei, def. (Jap)
    2. Inkoopmanagersindex industrie Caixin mei (Chi)
    3. Omzet detailhandel april (NL)
    4. DSM-Firmenich Beleggersdag
    5. Inkoopmanagersindex industrie mei, def. (Jap)
    6. Inkoopmanagersindex industrie mei def. (Dld)
    7. Inkoopmanagersindex industrie mei def. (VK)
    8. Inkoopmanagersindex industrie mei def. (eur)
    9. Inkoopmanagersindex industrie (S&P) mei def. (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda